Shares of Titan Pharmaceuticals (TTNP) ended the day with 14% up, after the company announced that its opioid addiction drug Probuphine achieved positive efficacy results in a phase 3 trial. Prior to joining the study, patients were receiving a maintenance type of treatment with an already approved drug combo of buprenorphine/naloxone 8mg or less for 3 months. 

The trial recruited up to 177 patients who were randomized into two different dose groups. One group took Titan's drug Probuphine together with sublingual tablets and the other group took sublingual tablets alone -- placebo -- for 6 months in total. The primary efficacy analysis of the study was to determine the comparison of responders in each group. Responders in the group were determined by being free of opioids for 4 to 6 months and by a self-made report afterwards. 

The primary efficacy analysis determined that the treatment with Titan's Probuphine implant, generated a response rate of 96.4%, while the placebo arm saw a response rate of 87.6%. Titan Pharmaceuticals now wants to submit an NDA to the FDA by the second half of 2015. If all goes well with the FDA Prophubine implant treatment for opioid addiction could potentially happen by the first half of 2016.